SCHEMBL19503274

SCHEMBL19503274

Cc1cc(C)c(C(C)C)c(N)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
IDO1 P14902 1/20 0.40
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
NOS3 P29474 2/20 0.37
NOS1 P29475 2/20 0.37
NOS2 P35228 2/20 0.37
TDP1 Q9NUW8 1/20 0.36
UHRF1 Q96T88 1/20 0.35
TERT O14746 1/20 0.34
POLB P06746 2/20 0.33
CDC7 O00311 1/20 0.33
PLK4 O00444 1/20 0.33
IKBKB O14920 1/20 0.33
AURKA O14965 1/20 0.33
CHUK O15111 1/20 0.33
ROCK2 O75116 1/20 0.33
FYN P06241 1/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10398503 0.83 NOS2 (0.45) MAPTNOS3NOS1NOS2TDP1
SCHEMBL20991797 0.77 KDM4E (0.40) KDM4EIDO1MEN1MAPTKMT2A
SCHEMBL10725037 0.77 ALDH1A1 (0.37) KDM4EMEN1MAPTKMT2ATDP1
SCHEMBL13438497 0.76 CYP1A2 (0.33) KDM4EMEN1MAPTKMT2APOLB
SCHEMBL21789250 0.76 KDM4E (0.33) KDM4EMEN1MAPTKMT2APOLB
SCHEMBL20285951 0.74 SMN1; SMN2 (0.47) MEN1KMT2APOLBCYP1A2ALDH1A1
SCHEMBL8344113 0.72 KDM4E (0.54) KDM4EIDO1MAPTKMT2ANOS3
SCHEMBL1279214 0.72 KDM4E (0.54) KDM4EIDO1MAPTKMT2ANOS3
SCHEMBL15000331 0.71 ALDH1A1 (0.32) KDM4ECYP1A2TLR9TLR8TLR7
SCHEMBL15000310 0.71 RECQL (0.34) KDM4ECYP1A2TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633371-B2 EZH2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-28 US disclosed
US-20200039968-A9 EZH2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-02-06 US disclosed
US-20190135796-A1 EZH2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-05-09 US disclosed
WO-2017184999-A1 EZH2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135796-A1 EZH2 INHIBITORS AND USES THEREOF EZH2, EZH1, BMI1 KDM4E 59/4885IDO1 2529/4885MEN1 1551/4885
US-20200039968-A9 EZH2 INHIBITORS AND USES THEREOF EZH2, EZH1, BMI1 KDM4E 59/4885IDO1 2529/4885MEN1 1551/4885
US-10633371-B2 EZH2 inhibitors and uses thereof EZH2, EZH1, BMI1 KDM4E 59/4885IDO1 2529/4885MEN1 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.